GEHC Expands Theranostics Imaging With 5 Global Collaborations

Impact · against what's priced in

The clinical collaborations for the StarGuide GX system provide incremental support for GEHC's long-term imaging growth, but they do not shift the current valuation which remains anchored to short-term EPS guidance and margin pressure. Because the market is currently discounting the bull case for imaging acceleration, these early-stage collaborations act as a slow-burn catalyst rather than a price-moving event.

GEHC+0.10

Challenges what's priced in

The price assumes

The bull case for the Imaging segment accelerating growth via the IB Clinic platform and a massive backlog, worth roughly 15%.

The market is currently not paying for an acceleration in the Imaging segment; these five new global collaborations for the StarGuide GX system provide the clinical validation necessary to eventually drive that growth.

• healthcare
• GEHC
• cancer diagnosis
• clinical trials
• medical imaging
• nuclear medicine
• precision medicine
• theranostics

Search tags